Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pfizer Inc. is conducting a clinical study titled ‘AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR.’ The study aims to assess the effectiveness and safety of elranatamab, alone and in combination with daratumumab, compared to a standard treatment regimen in patients with multiple myeloma who have undergone prior treatments.
The study tests two main interventions: the BCMA-CD3 bispecific antibody elranatamab and the anti-CD38 monoclonal antibody daratumumab. These treatments are intended to improve outcomes for patients with relapsed or refractory multiple myeloma.
This interventional study is randomized and follows a factorial design without masking, focusing on treatment as the primary purpose. Participants are assigned to different treatment arms to compare the efficacy and safety of the interventions.
The study began on October 4, 2021, and is currently recruiting participants. The last update was submitted on June 23, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
The results of this study could significantly impact Pfizer’s stock performance by potentially enhancing its oncology portfolio. It may also influence investor sentiment positively if the outcomes are favorable, especially in the competitive landscape of multiple myeloma treatments.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.